FDA Initiates Safety Study on Abortion Pill Mifepristone Amid Controversy
The Food and Drug Administration (FDA) is conducting a safety study on the abortion pill mifepristone, as confirmed by a senior FDA official. This study, which is retrospective and involves hundreds of thousands of cases, could potentially lead to restrictions on the medication's access. The interim results are expected in July, with the final results dependent on a secondary analysis. The study has been ongoing for months, focusing on data already collected by the agency. This development follows a memorandum from the Biden administration that lifted restrictions on mifepristone, allowing it to be dispensed via telehealth and mail. However, a lawsuit from Louisiana challenged this decision, leading to a temporary reinstatement of in-person dispensing by the U.S. Court of Appeals for the 5th Circuit, which was later set aside by the Supreme Court. 
